- Report
- May 2025
- 195 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 180 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 147 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- August 2024
- 147 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- May 2025
- 138 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- February 2025
- 150 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- May 2025
- 195 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- March 2025
- 120 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- March 2025
- 120 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- August 2024
- 208 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- July 2024
- 180 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- September 2024
- 253 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- March 2025
- 252 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- June 2025
- 67 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 278 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 193 Pages
Global
From €5240EUR$5,850USD£4,467GBP

RNA interference (RNAi) is a biotechnological process that uses small pieces of double-stranded RNA (dsRNA) to inhibit gene expression. It is a powerful tool for studying gene function and has been used to develop treatments for a variety of diseases. RNAi has been used to target and silence specific genes, allowing researchers to study the effects of gene silencing on cell function. It has also been used to develop treatments for cancer, viral infections, and other diseases.
RNAi technology has been used to develop a variety of therapeutics, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides (ASOs). siRNAs are short pieces of dsRNA that can be used to target and silence specific genes. miRNAs are small pieces of single-stranded RNA that can regulate gene expression. ASOs are short pieces of DNA that can be used to target and silence specific genes.
The RNAi market is a rapidly growing segment of the biotechnology industry. Companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioNTech, Editas Medicine, and Moderna Therapeutics. These companies are developing a variety of RNAi-based therapeutics for a range of diseases. Show Less Read more